[go: up one dir, main page]

MX2021002916A - Pirfenidona enriquecida con deuterio y métodos para su uso. - Google Patents

Pirfenidona enriquecida con deuterio y métodos para su uso.

Info

Publication number
MX2021002916A
MX2021002916A MX2021002916A MX2021002916A MX2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A
Authority
MX
Mexico
Prior art keywords
methods
deuterium
enriched
pirphenidone
compounds
Prior art date
Application number
MX2021002916A
Other languages
English (en)
Inventor
Eric Elenko
Michael C Chen
Luann Sabounjian
Original Assignee
Puretech Lyt 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt 100 Inc filed Critical Puretech Lyt 100 Inc
Publication of MX2021002916A publication Critical patent/MX2021002916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen compuestos de N-aril piridinona enriquecida con deuterio, opcionalmente en combinación con uno o más agentes terapéuticos adicionales, las composiciones farmacéuticas que los comprenden, los métodos para su preparación y los métodos para su uso. Tales compuestos y composiciones son útiles, por ejemplo, en el tratamiento de enfermedades, trastornos o afecciones como el edema.
MX2021002916A 2018-09-14 2019-09-16 Pirfenidona enriquecida con deuterio y métodos para su uso. MX2021002916A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731570P 2018-09-14 2018-09-14
US201862750377P 2018-10-25 2018-10-25
US201962839256P 2019-04-26 2019-04-26
US201962884984P 2019-08-09 2019-08-09
PCT/US2019/051369 WO2020056430A1 (en) 2018-09-14 2019-09-16 Deuterium-enriched pirfenidone and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021002916A true MX2021002916A (es) 2021-08-24

Family

ID=68073243

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002916A MX2021002916A (es) 2018-09-14 2019-09-16 Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2024013040A MX2024013040A (es) 2018-09-14 2021-03-11 Pirfenidona enriquecida con deuterio y metodos para su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013040A MX2024013040A (es) 2018-09-14 2021-03-11 Pirfenidona enriquecida con deuterio y metodos para su uso

Country Status (11)

Country Link
US (2) US20200093810A1 (es)
EP (2) EP3849551A1 (es)
JP (2) JP2022501427A (es)
KR (1) KR20210076000A (es)
CN (1) CN112996508A (es)
AU (2) AU2019339536A1 (es)
CA (1) CA3112765A1 (es)
IL (3) IL312572A (es)
MX (2) MX2021002916A (es)
SG (1) SG11202102581YA (es)
WO (1) WO2020056430A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010925A1 (en) * 2020-07-06 2022-01-13 Puretech Lyt 100, Inc. Methods of treating diseases and disorders with deupirfenidone
WO2021181368A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
WO2021186401A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
CN117615765A (zh) * 2021-05-03 2024-02-27 蒂罗纳生物股份有限公司 用ALK-5(TGFβR1)抑制剂治疗肺部疾病的方法
EP4460305A1 (en) * 2022-01-05 2024-11-13 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CN115337315A (zh) * 2022-07-13 2022-11-15 陕西慧康生物科技有限责任公司 三氮脒在制备治疗肝纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
KR100898888B1 (ko) 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2(1ｈ)피리디논의 제조 방법
ES2400026T3 (es) * 2007-06-20 2013-04-05 Auspex Pharmaceuticals, Inc. N-arilpiridinonas sustituidas como inhibidores fibróticos
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
WO2014134132A1 (en) 2013-02-26 2014-09-04 University Of Louisville Research Foundation, Inc. Milk-derived microvesicle compositions and related methods
EP3096758A1 (en) 2014-01-24 2016-11-30 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
AU2016215173B2 (en) * 2015-02-05 2019-11-21 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents

Also Published As

Publication number Publication date
EP4427815A2 (en) 2024-09-11
CA3112765A1 (en) 2020-03-19
US20210205283A1 (en) 2021-07-08
JP2025000646A (ja) 2025-01-07
CN112996508A (zh) 2021-06-18
IL319182A (en) 2025-04-01
US20200093810A1 (en) 2020-03-26
EP4427815A3 (en) 2024-11-06
JP2022501427A (ja) 2022-01-06
AU2025204570A1 (en) 2025-07-10
WO2020056430A1 (en) 2020-03-19
KR20210076000A (ko) 2021-06-23
IL281420A (en) 2021-04-29
EP3849551A1 (en) 2021-07-21
MX2024013040A (es) 2024-11-08
SG11202102581YA (en) 2021-04-29
IL312572A (en) 2024-07-01
AU2019339536A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX385332B (es) Moduladores de ror-gamma.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201792047A1 (ru) Новые соединения
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
PH12021550872A1 (en) Therapeutic compounds
EA201990400A1 (ru) Соединения и композиции и их применение
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA202090270A1 (ru) Новые замещенные производные ксантина
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112021014566A2 (pt) Moduladores de gpr35
BR112016004904A8 (pt) moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7